Trial Profile
A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients with Moderate-to-Severe Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jan 2022
Price :
$35
*
At a glance
- Drugs Ixekizumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms IXORA-P
- Sponsors Eli Lilly and Company
- 23 Sep 2019 Results assessing indirect comparison of long-term efficacy of every-two week versus recommended dosing of ixekizumab by using data from four studies (IXORA P, UNCOVER 1, 2 and 3) published in the British Journal of Dermatology.
- 10 Sep 2018 According to an Eli Lilly media release, data from this trial will be presented at the 27th annual European Academy of Dermatology and Venereology (EADV) Congress (Sep 2018).
- 06 Feb 2018 Primary endpoint has been met. (Proportion of Participants Achieving 75% Improvement in Psoriasis Area and Severity Index (PASI 75) in Q2W dose group versus the Q4W dose group) as per results published in British Journal of Dermatology.